Clinical trials: Chronic Pruritus
Allergic Rhinoconjunctivitis, Chronic Urticaria
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population…
- Trial name
- NCT01081574
- Testing
- Bilastine
- Where
- 7 sites in Australia, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- Faes Farma, S.A.
Chronic Pruritus Due to Plaque Psoriasis
An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy
To assess the benefit of the Avène hydrotherapy in subjects with pruritic plaque psoriasis
- Trial name
- PAP (NCT03023254)
- Testing
- Hydrotherapy
- Where
- 29 sites in France, Spain
- Volunteers
- 44 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in…
- Trial name
- REMIX-1 (NCT05030311)
- Testing
- LOU064 25 mg (b.i.d), LOU064 25 mg (b.i.d) as a tablet.
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
- Trial name
- NCT06262607
- Testing
- CLE-400, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Clexio Biosciences Ltd.
Uremic Pruritus
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
- Trial name
- NCT05885737
- Testing
- Difelikefalin Injection
- Where
- 35 sites in China
- Volunteers
- 260 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Prurigo Nodularis, Nodularis Prurigo
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to…
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
- Trial name
- NCT02174419
- Testing
- nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- Trevi Therapeutics
Atopic Dermatitis
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
- Trial name
- NCT02651714
- Testing
- Tradipitant
- Where
- 28 sites in United States
- Volunteers
- 168 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Kidney Disease-associated Pruritus
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
Vifor International Ltd. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.
- Trial name
- CKD (NCT05625542)
- Sponsor
- Vifor (International) Inc.
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Pruritus, Chronic Kidney Diseases
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Rationale: People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.
- Trial name
- NCT06593392
- Testing
- Difelikefalin
- Where
- 18 sites in China, Greece and 5 more
- Volunteers
- 18 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Chronic Spontaneous Urticaria
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the…
- Trial name
- NCT05513001
- Testing
- LOU064 (blinded), LOU064 (open label)
- Where
- 208 sites in United States, Argentina and 28 more
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07811869
- Testing
- Remibrutinib
- Where
- 10 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease-associated Pruritus
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
Vifor International Inc. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.
- Trial name
- ReliefCensus (NCT05524467)
- Where
- 94 sites in Germany, Italy and 5 more
- Volunteers
- 3,100 people
- Sponsor
- Vifor (International) Inc.
Chronic Inducible Urticaria
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
- Trial name
- PEARL-PROVOKE (NCT05024058)
- Testing
- Ligelizumab
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07700056
- Testing
- Remibrutinib
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Prurigo Nodularis, Nodularis Prurigo
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo
- Trial name
- NCT02174432
- Testing
- nalbuphine HCl ER
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Trevi Therapeutics
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Uremic Pruritus
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
- Trial name
- NCT03998163
- Testing
- CR845 0.5 mcg/kg
- Where
- 47 sites in United States, Czechia and 2 more
- Volunteers
- 222 people
- Sponsor
- Cara Therapeutics, Inc.
Chronic Kidney Disease-associated Pruritus
The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).
- Trial name
- ITCHINESS (NCT05482698)
- Testing
- MC2-25 cream, MC2-25 vehicle
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- MC2 Therapeutics